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ABSTRACT 
For many years Familial Hypercholesterolemia (FH), an inherited disorder, has been 
diagnosed using phenotypic features plus family history of early onset cardiovascular 
disease (CVD), and has been successfully treated using statin therapy. DNA testing is 
now available and this has been incorporated into familial cascade screening 
programmes in many parts of Europe. Little is known about patients’ perceptions of 
the value of undergoing molecular diagnosis for FH. In-depth interviews were carried 
out with patients (n=38), being treated for FH who were the first in their family to 
undergo DNA testing for FH. Data were analysed thematically. While interviewees 
regarded DNA testing as an unexceptional event, it was seen as a positive innovation 
because it: confirmed that their family carried a particular disorder, offered an 
aetiological explanation for their hypercholesterolemia and provided information 
about their own and family members’ future risks. From the patient perspective, the 
main benefit of molecular diagnosis lies in its ability to provide information which 
allows (younger) family members to access genetic screening and, thus, timely 
treatment. The implications for future developments in genetic services and the need 
to investigate further the provision of molecular testing in mainstream specialties are 
briefly discussed. 
Keywords: Familial Hypercholesterolemia (FH), molecular diagnosis, patient 
experience, qualitative interviews, genetic screening 
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INTRODUCTION 
Diagnosis organises and classifies corporeal states, identifies treatment, provides 
prognostic and aetiological information, determines what is “normal”, enables access 
to services, sanctions and creates social roles and structures relationships between 
patients and healthcare professionals. As such, diagnosis is a fundamental aspect of 
medical care (Jutel, 2009). The relationship between diagnostic procedures and 
diagnostic categories is dynamic, with diagnostic categories being constantly refined 
in light of changes in knowledge and technological advances (Jutel, 2009). This can 
be clearly seen in the field of inherited disorders; indeed, Hedgecoe (2003) describes 
how certain diseases or bodily traits have come to be redefined as genetic following 
the introduction of molecular diagnostics. DNA technologies have not only changed 
the ways in which we perceive some diseases, but also our view of diagnostic 
processes (Lippman, 1991,1992; Miller et al., 2006). As various studies have 
highlighted, healthcare professionals and patients can regard DNA testing as 
providing immutable or definitive diagnostic categories and more authoritative 
predictions of future risks of disease in individuals (Miller et al., 2005; Horstmann, 
2008).  
This paper describes patients’ perceptions of molecular diagnosis for Familial 
Hypercholesterolemia (FH), an inherited cardiovascular disorder, which, until 
relatively recently, was diagnosed using a combination of phenotypic features and 
family history of cardiovascular disease (CVD). Like diagnostic DNA testing for 
other late onset disorders, DNA testing for FH often takes place outside of clinical 
genetics; in this instance, within the lipid clinic. Earlier research has looked at the 
impact of genetic diagnosis for FH on individuals’ beliefs about the aetiology of 
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disease and their preventative behaviours (Senior et al., 2002; Hollands et al., 2012). 
Senior et al (2002) interviewed patients with FH who subsequently underwent genetic 
testing as part of the GRAFT (Genetic Risk Assessment for FH Trial, Marteau  et al., 
1999) study, which compared the impact of molecular versus non-molecular 
diagnosis; they found that this group attributed their FH to genetic causes, which 
many saw as absolving them of responsibility for causing their disease.   However, 
this research has failed to specifically explore individuals’ views about the value of 
obtaining a molecular diagnosis. It can be argued that it is important to look at 
patients’ perceptions of the value of molecular testing as a diagnostic tool, particularly 
within mainstream specialties, not least because it is predicted that DNA testing for 
common and/or complex disorders, like hypercholesterolemia, cancer and type 2 
diabetes, may become a major part of the diagnostic repertoire in many clinical 
specialties in the near future (PHG Foundation, 2011).  
Familial Hypercholesterolemia (FH) 
FH is an autosomal dominant disorder affecting one in 500 people (DeMott et al, 
2008). It is characterised by high levels of low density lipoprotein (LDL) cholesterol, 
which, if left untreated, greatly increase individuals’ risks of CVD - 50% for men 
aged 50 years and 30% for women aged 60 years (DeMott et al, 2008). Individuals 
who carry a pathogenic mutation may have coronary events at an earlier age, with 
those under 40 years having a nearly 100 times increased risk of fatal heart attack 
(Marks et al., 2006). FH is usually treated by statin therapy, which significantly 
reduces morbidity and mortality from CVD (DeMott et al, 2008). The severity of the 
consequences and the treatability of hypercholesterolemia means that familial 
screening for FH has been actively promoted by WHO for nearly twenty years (WHO, 
1998).  
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Historically, the diagnosis of probable FH was based upon raised levels of LDL 
cholesterol and a family history of early onset CVD, whereas a definite diagnosis also 
required the presence of tendon xanthomata (visible cholesterol deposits) (Simon 
Broome, 1999). DNA testing for FH mutations is now available, and this can be used 
to confirm preexisting clinical diagnoses (diagnostic testing) and identify (younger) 
pre-symptomatic individuals as carrying a mutation (predictive testing) (Civeira et al., 
2008; van Aalst-Cohen et al., 2006). It has been argued that familial screening for FH 
may be a cost-effective way of reducing premature death from CVD, hence DNA 
cascade screening programmes have been implemented in some European countries 
and some parts of the UK (Finnie, 2010; Marks et al., 2002). 
In Scotland, patients attending specialist lipid clinics, who have a clinical diagnosis of 
FH, have been asked to provide blood samples for molecular testing since 2010. If a 
pathogenic mutation is identified, the index patient is referred to clinical genetics to 
discuss their result and identify relatives for cascade screening. Family members are 
diagnosed by DNA testing in the genetics clinic and then referred to specialist lipid 
services for their clinical management (see Hallowell et al., 2011, Box 1).  The 
qualitative study reported in this paper was carried out following the implementation 
of the Scottish DNA cascade screening programme. We sought to investigate index 
patients’ experiences of undergoing DNA testing as part of the screening programme. 
We have previously reported their perceptions of the organisation of familial cascade 
screening (Hallowell et al., 2011) and the impact of DNA testing on risk perceptions 
and health behaviours (Jenkins et al., 2011). This paper reports data on their views of 
the value of obtaining a molecular diagnosis for FH.  
METHODS 
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Recruitment 
One hundred and fourteen patients, who had a clinical diagnosis of FH and had 
undergone DNA screening in two lipid clinics in SE Scotland, were invited to take 
part in an interview. Patients were sent an invitation from the lead clinician, a study 
information sheet and an expression of interest form to return to the qualitative 
research team in a pre-paid envelope.  
Sampling  
DNA testing of index patients who have a clinical diagnosis of FH produces one of 
two results; a positive result which confirms the individual carries an FH mutation or 
an inconclusive result, which reveals they do not carry any of the pathogenic 
mutations covered by the test. The latter is not a negative DNA result, as it is possible 
that the individual’s (and family’s) hypercholesterolemia is caused by another genetic 
mutation, which can give rise to the FH phenotype. Given our interest in individuals’ 
experiences of undergoing molecular diagnosis, we purposively sampled two groups; 
patients receiving a positive  result and patients receiving an inconclusive  result. 
Within each group, we tried to achieve a balanced sample with regard to gender and 
age profile, in line with earlier research (Weiner, 2009; Weiner and Durrington, 
2008). Recruitment ceased once data saturation occurred.  
Data collection and analysis 
NJ conducted the interviews at a time and location chosen by participants. With one 
exception, an online interview using instant messaging, interviews were carried out 
face-face. Interview topic guides were informed by the literature, observations of 
consultations in both lipid and genetics clinics previously undertaken by NH and NJ 
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for familiarization purposes, and findings emerging from an analysis of initial 
interviews. The interviews explored: personal and familial disease histories, 
experiences of managing hypercholesterolaemia, experiences of DNA testing and 
obtaining and interpreting DNA results; and, the impact of DNA testing on risk 
perception, risk management and health behaviours. Data collection and analysis took 
place concurrently, allowing issues identified in early interviews to inform the areas 
explored in later ones (Strauss  and Corbin, 1990). Data collection ceased at the point 
where no new themes emerged from the analysis of new interviews. 
Interviews were: recorded, transcribed, anonymised and analysed using a thematic 
approach (Strauss and Corbin, 1990). The research team systematically compared the 
transcripts of those receiving different types of DNA results to identify crosscutting 
themes and to highlight common and divergent experiences. A coding frame was 
developed to capture data relating to the primary research aims as well as emergent 
themes. Data were managed using NVivo 8 (QSR International, Victoria, Australia). 
Although not explicitly asked to comment on the benefit of DNA versus biochemical  
diagnosis, interviewees’ perceptions of the value of DNA diagnosis emerged as a 
substantive theme in the analysis. As the analysis suggests, both those who received a 
positive result and those who received an inconclusive result identified a number of 
benefits of DNA diagnosis. 
RESULTS  
Participants 
Thirty-eight individuals were interviewed. The gender split (women:men)  was 55:45. 
Most interviewees (79%) were aged over 45 years, 42% had university level 
education and the majority were working/had worked in a higher socio-economic 
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occupation. Roughly a third were long-term (>10years) clinic patients, while a third 
were novices, having been referred to the lipid clinic within the last two years. Most 
interviewees  (31, 82%) reported a family history of CVD/hypercholesterolemia and 
31 (82%) had biological children. Twenty-three (61%) received a positive result 
following DNA testing and 15 (39%) of these had attended the genetics clinic to 
discuss their result prior to their interview.  
DNA diagnosis for FH: an unexceptional event or unexceptional test?  
Most interviewees described DNA testing as “a bit of a non-event” (FH04, Positive) 
or as having had little or no impact on their lives, with two patients failing to recall 
the outcome of their DNA test. This lack of engagement was justified by the fact that 
genetic test results had not altered pre-existing disease management regimens (see 
also Jenkins et al., 2011).  
FH06 I’m taking statins now so whether I, whether I’d had the genetics test or not I 
was already on a course of statins and statins have reduced my cholesterol level . 
Positive 
FH07 I need to manage my condition for me, and I’ve been doing that and I don’t see 
that any sort of genetic imbalance there or genetic issue would have changed how I 
would have had to manage that. Inconclusive  
When discussing their reactions to undergoing DNA testing, most interviewees 
compared molecular diagnosis for FH, not with their earlier clinical diagnosis, but 
with DNA testing for other conditions. Drawing these comparisons led them to 
conclude that, when compared with other types of genetic testing (e.g., for 
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Huntington’s Disease (HD) or inherited cancers), genetic testing for FH appears to 
have less threatening (potential) consequences. 
FH11 It [DNA testing for FH] is not predicting what ghastly things are going to 
happen to you if you get this thing in the future … You don’t have to plan your life 
around it. You don’t have to wonder, can you have children or not. Inconclusive  
 FH04 I mean, it’s not that bad, you know, particularly given the good medication 
that’s around. It’s not like having something like Huntingdon’s or something like that, 
you know, where you’ve got a 50% chance of having some terminal and incurable 
condition. It’s not the same. Positive 
Thus, interviewees’ views of DNA testing for FH appeared to be influenced by their 
wider perceptions of FH. Many commented that hypercholesterolaemia is easily 
managed with medication, unlike cancer, which, as FH18 (Positive) reflected, “[bowel 
cancer]…carries many more implications for your future.” Thus, DNA testing for FH 
was constructed as a more benign intervention than predictive testing for colorectal or 
breast cancer, primarily because having a predisposition to elevated cholesterol was 
not perceived as “life- threatening”.  
FH09 I don’t truly see high cholesterol as being treated as life -threatening. 
…different if you had a form of cancer that’s hereditary and it’s going to kill you or 
it’s going to have fairly serious consequences to you. Inconclusive  
The perceived usefulness of DNA diagnosis  
If interviewees have already obtained a clinical diagnosis and are successfully 
managing their hypercholesterolemia with statin therapy, what is the value of a 
molecular diagnosis? Does receiving a molecular rather than a clinical diagnosis have 
11/4/16 2:40 PM 
 10 
any perceived benefits for patients, or is it, as FH04 (Positive) commented, just 
regarded as a more expensive “… sledgehammer to crack a nut”?  
FH04 I still can’t see the point of this expensive test to do something that a simple 
blood test [serum cholesterol test] will do. Positive 
FH04 was in a minority, for most interviewees saw molecular diagnosis as having 
some value over and above receiving a clinical diagnosis based on phenotypic 
markers. In discussing the perceived benefits of DNA testing for FH, interviewees 
described molecular testing as performing a number of the accepted functions of 
diagnostic tests, namely: classifying or relabeling symptoms, providing aetiological 
explanations and providing information about the future, i.e., prognostic or risk 
information.  
Classifying symptoms  
While for some DNA testing merely confirmed their pre-existing clinical diagnosis, 
for a small group it provided a new, and definitive, diagnostic label. Before 
undergoing DNA testing a couple of interviewees had been diagnosed as having “high 
cholesterol” or some unspecified hyperlipidemia. Molecular diagnosis, therefore, 
identified them as having a particular condition – FH.  
FH37 [Dr] says “we’ve got a name for what you’ve got!” He was quite chuffed, and 
he said “oh, after all these years of seeing you I now have a name for what you’ve 
got, after all these years of just treating you for high cholesterol and here we go, it’s a 
genetic thing” Positive  
Thus, for a minority, molecular diagnosis resulted in the classification of pre-existing 
symptoms as a specific disease entity. While the classificatory function of DNA 
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testing may have had little impact on the majority, many interviewees observed that 
receiving a molecular diagnosis was important because it provided them with an clear 
aetiological explanation for their hypercholesterolaemia. 
Providing aetiological explanations and removing uncertainty  
Many interviewees who received a confirmatory result described their DNA test result 
as providing an explanation for their own (and their family’s) hypercholesterolemia.  
FH13 it’s confirming what we thought … it’s definitely confirming it, you know what I 
mean, as opposed to “I think you’ve got it”, as opposed to what maybe the lipid clinic 
said, “your results show that you’ve a tendency” but it does actually confirm that it is 
a family problem. Positive 
Indeed, molecular diagnosis was constructed as a positive development because it 
provided individuals with a degree of certainty or undisputable evidence about the 
genetic cause of their hypercholesterolemia.  
FH21 If there hadn’t been genetic testing there then I probably would have been 
sitting here going, well, maybe it’s lifestyle, maybe it’s genetic, can’t really tell. We 
think it’s probably passed down , but we can’t prove it. And you’d be sort of sitting 
there with more questions than answers. Positive 
Moreover, it confirmed that they were managing their hypercholesterolemia correctly. 
FH 40 And certainly the genetic testing takes that element of uncertainty out.  It hasn’t 
changed the treatment in any way because I was already getting treated , but it has 
taken that element of uncertainty away…. Positive 
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By providing a genetic explanation for disease, DNA testing potentially reallocates 
blame, in the sense that disease becomes an internalised or individual, rather than a 
social or environmental, problem. In this instance the individualising effect of 
receiving a molecular diagnosis was seen as working in the interviewees’ favour, 
primarily because this aetiological explanation absolved them of the responsibility for 
causing their hypercholesterolemia. Thus, for some, obtaining a DNA diagnosis 
challenged the view that hypercholesterolemia is caused by bad habits or irresponsible 
living. This observation may partly explain why molecular diagnosis was so firmly 
embraced by those identified as carrying a pathogenic mutation, and is further 
supported by the reactions of some who received an inconclusive test result, who said 
they felt disappointed as they still had to counter others’ “mis”perceptions that they 
were in some way responsible for causing their hypercholesterolemia.  
FH29 [I was] almost disappointed [to receive inconclusive result]. ….I don’t think 
I’m causing my high cholesterol but it would be very easy then to turn round to people 
and say, well actually, it’s in my genes and that’s it. … So I was actually almost 
disappointed 'cause it would have been nice to say that it [genes] was the cause. 
Inconclusive 
Although DNA diagnostics provided those who tested positive with some answers, 
this was not the case for those who had received an inconclusive result, as FH29 
indicates, these individuals were left in a state of uncertainty. Some of these 
interviewees did appear to feel short-changed that they had not received a 
confirmatory DNA diagnosis, as FH19 (Inconclusive) said: “I would rather have 
found out that, you know, is it a genetic thing because if it’s a genetic thing, there’s 
nothing you can do about it.” 
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Our interviewees not only drew upon discourses of responsibility when talking about 
the aetiology of FH within themselves, but also when discussing the intergenerational 
transmission of FH mutations. A few, who had had their mutation status confirmed, 
acknowledged the familial aspects of genetic transmission and expressed a concern 
that their children may have (or had) inherited their FH mutation.  
FH05 Yeah, because you think “well, that’s something that I’ve passed on”. That 
would bother me more than me having it because it doesn’t affect me at all , but I 
would hate to think that I’d given one of my kids something like  that. Positive  
In sharing their worries about their children being at–risk, interviewees reflected upon 
the role of DNA testing in revealing future risks, and many regarded this as a major 
benefit of molecular diagnosis.  
Revealing the future  
While most of the interviewees in both groups did not see their own risks of CVD as 
altered by their DNA results, there were a couple of exceptions. FH13, for example, 
described how learning that he had FH, rather than just “high cholesterol” had 
heightened his risk perception.  
 FH13 I got maybe the impression that the hypercholesterolemia is really more to do 
with family connections, or the family side of it was important but I didn’t quite 
realize… it is a more serious type of disease than just the straightforward 
hyperlipidemia… I suppose I do see myself as a higher risk now, obviously. Positive  
Although DNA diagnosis appeared to have had negligible impact on personal risk 
perceptions for the majority, nearly all saw DNA testing as valuable because it 
presented them with the possibility of predicting disease risk within the wider family. 
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Many interviewees with young children, like FH42, emphasized how a DNA 
diagnosis could help to establish definitively and early on whether or not their 
(asymptomatic) children had FH.  
FH42 I’m very pleased to know that in the future – I’ve got two children … I intend to 
bring them up with healthy eating habits and healthy lifestyle but not having the stress 
of having the worry, I don’t want them to have to worry about it.  If you get the genetic 
test done, it takes the worry away, it’s a definitive “yes” or “no”.  If it’s a “yes” then 
you treat it …Positive  
Others stressed the importance of obtaining a DNA diagnosis for other young 
relatives.  
FH18 I suppose it was looking backwards, and I suppose particularly my uncle, with 
my uncle having five children, all of whom had children, I suppose I saw an 
opportunity there to tell all of them “look, don’t worry! [you can find out] ” you 
know. Positive  
A few interviewees who had received an inconclusive result were disappointed their 
wider family was unable to have predictive testing. These interviewees said that they 
would have liked to have established their young children’s mutation status, so that 
they could start to manage their risk at an early age; for example, by modifying the 
family diet.  
FH07 ...but that’s what you give them, you give them whole milk, full-fat. Does that 
change if there is a genetic cholesterol issue? Do we need to start thinking about that 
now rather than giving them all the ‘green milk’ as I call it when they’re six-ish, 
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which again is the advice or...? So those are the things I’ve been thinking about. 
Inconclusive  
DISCUSSION 
This paper has explored patients’ views of the use of DNA technologies in the 
diagnosis of FH. The data suggest that undergoing molecular diagnosis only had a 
modest impact upon interviewees, which may be due to the fact that receiving a DNA 
test result (or not) did not change the ways they managed their hypercholesterolemia 
(Jenkins et al; 2011; Senior et al., 2002 Hollands et al, 2012; Hardcastle et al., 2015).  
However, while DNA testing may have had little effect on risk management behavior 
and intentions, it was perceived as having some benefits: it provided an aetiological 
explanation and diagnostic label, confirmed current risk management practices, 
absolved individuals of blame for their hypercholesterolemia and provided 
information which other family members could use to access timely diagnoses and 
treatment (See Hallowell et al., 20003). Thus, as far as our interviewees were 
concerned, DNA testing for FH, was generally regarded as a worthwhile or valuable 
activity. These views contrast with those of healthcare professionals working in 
primary and secondary care who regard DNA testing for FH as inaccurate, time 
consuming, expensive and as adding little value to their clinical practice (Will et al., 
2010).  
The data suggest that DNA testing undertaken within a mainstream lipid clinic is not 
perceived as an exceptional or anxiety provoking experience (see also Jenkins et al, 
2011; Hallowell et al, 2011). Saukko et al (2006) similarly report that individuals 
undergoing screening for genetic susceptibility to thrombophilia in primary and 
secondary care see this procedure as generating useful information, but not as an 
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unexceptional or unusual event. Indeed, like us, they observed that a substantial 
proportion of people they interviewed did not recall having had a “genetic” test 
(Saukko et al., 2006). These authors speculate that these reactions were influenced by 
the fact that the DNA testing for thrombophilia is for very low risk genetic 
susceptibilities, which have little or no impact on health or its management. Our 
findings similarly support the hypothesis that perceived risks rather than objective risk 
estimates may influence patients’ views of DNA testing.  Indeed, despite the fact that 
FH objectively increases individuals’ risk of CVD if left untreated, it was clear that 
our interviewees did not perceive FH as a particularly risky or threatening condition, 
when compared with cancer and neurological disorders, therefore, confirming their 
diagnosis of FH was not seen as personally threatening. This view may be based upon 
their experiences of successfully (and easily) treating their hypercholesterolemia with 
statin therapy (Jenkins et al., 2011; Hollands et al, 2012; Hardcastle et al., 2015); 
alternatively, it may due to the fact that cultural conceptions of cancer and CVD are 
very different. Finally, it must be noted the drawing of downward social comparisons 
to modulate risk was also observed by Senior et al, (2002), who report that some 
patients in their study described the risks of CVD caused by FH as comparing 
favourably with those of other genetic diseases such as sickle cell disease. 
Some of the findings reported in this study have also been documented by Weiner 
(2009 and 2011), who investigated the views of patients being treated for FH, who 
had not been offered DNA testing and Hollands et al., (2012) who compared the 
views of first and second degree relatives of FH patients undergoing either clinical or 
molecular diagnosis. The participants in both studies similarly regarded a diagnosis of 
FH as absolving them of responsibility for causing their hypercholesterolaemia 
(Weiner, 2009 and 2011; Hollands et al., 2012, Senior et al., 2002). Furthermore, like 
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our patients (Jenkins et al., 2011), the interviewees in Weiner’s and Hollands et al’s 
studies regarded their risk management activities as vindicated. Thus, it could be 
argued that phenotypic diagnosis in Weiner’s and Hollands et al.’s studies performed 
a very similar function to molecular diagnosis in the current study. However, there is 
an important difference between our findings and those of Hollands et al., (2012) and 
Weiner (2011); namely, our interviewees’ emphasis on the predictive value of 
molecular diagnosis for the wider family. Although Weiner (2011) reports that some 
of her interviewees acknowledged the familial aspects of their hypercholesterolemia, 
she suggests that their accounts of disease causation were not highly geneticised and 
that few regarded themselves as having an obligation or responsibility to ensure that 
other family members sought information about their risks of FH (Weiner, 2011). In 
contrast to Weiner (2011) and Hollands et al., (2012) the predictive value of 
molecular diagnostics for other family members was emphasized by our interviewees, 
who, like those described by Horsten and Smand (2008), regarded it as one of its 
greatest assets, not least because they recognized that molecular testing is the only 
way to confirm that their younger relatives can be offered more timely access to 
treatment (Jenkins et al., 2011).  
There are a couple of explanations for these observed differences. First, none of 
Weiner’s (2011) interviewees and only 50% of Hollands et al.’s (2012) underwent 
molecular diagnosis; therefore, it is hardly surprising that their interviewees did not 
reflect on the predictive value of DNA testing. Second, while half of Holland et al.’s 
interviewees did have a DNA test, it is unclear whether the predictive value of testing 
was addressed in the semi-structured interviews. Finally, we observed that when 
genetic testing was discussed in the lipid clinics and in genetic consultations in our 
study, healthcare professionals discussed the implications of receiving a diagnosis of 
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FH for patients’ relatives when they were advising them about initiating a familial 
cascade. Given that over a third of our interviews had attended a cascade consultation 
before being interviewed, it was perhaps unsurprising that our interviewees 
emphasized the importance of a receiving a DNA diagnosis for family members when 
questioned; although, it can be argued that they only did so because this resonated 
with their understandings and priorities. However, it can be speculated that 
perceptions of the usefulness of molecular diagnosis for self and other family 
members may be influenced by the ways the healthcare professionals’ frame disease 
and DNA diagnostics, a point that has been acknowledged by Weiner (2011). While a 
number of studies have explored the ways in which genetic information is presented 
within the genetics clinic (see for example, O’Doherty, 2006;2009; Arribas Allyon et 
al., 2011) we are unaware of research which has looked at the ways in which DNA 
testing is presented and framed by other clinical specialists within mainstream 
medicine.  We suggest that there is a need for more research that looks at the ways in 
which (the value of) molecular diagnosis is presented within mainstream medicine by 
non-genetics specialists; particularly, as this group may be increasingly charged with 
providing these services in the future. 
Finally, in contrast, to Hollands et al.’s (2012) observations that some of their 
interviewees described their social identity as negatively impacted by a positive 
(clinical/molecular diagnosis) of FH, our study suggests that receiving molecular 
confirmation of a clinical diagnosis of FH can be seen as providing patients with some 
form of biographical reinforcement (Carricaburu and Pierret,1995). There was 
evidence that DNA testing had a positive effect on identity, it not only established 
one’s identity as a person with a familial or genetic disease, but also confirmed that 
one is managing hypercholesterolemia in appropriate ways (Hardcastle, et al., 2015). 
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Indeed, the implicit value of molecular diagnosis in this respect was reinforced by the 
responses of some of those who received an inconclusive result, who appeared to 
struggle with ongoing uncertainty about personal and familial risks and risk 
management. 
Study Limitations 
Prior to concluding it is important to reflect upon the study’s limitations. While a 
qualitative design enabled the collection of rich data about patients’ experiences of 
undergoing molecular diagnosis in a mainstream specialty, it could be argued that this 
study suffers from an ascertainment bias. All the patients had already been identified 
as having hypercholesterolemia and were successfully treating it, some for many 
years, thus while DNA testing could confirm their clinical diagnosis it did not provide 
them with a new diagnosis per se. Given these observations, it could be argued that if 
we are interested assessing the perceived benefits of DNA testing, then it is important 
to gauge the views of those who have not been previously identified as having 
hypercholesterolemia or those who have a family history of disease. A prospective 
study of the perceptions and experiences of FH naïve individuals undergoing 
opportunistic DNA screening for FH during genome/exome sequencing as per the 
ACMG’s recommendations (Green et al., 2013), could potentially overcome these 
shortcomings.  We must also draw attention to the fact that our sample was relatively 
well-educated (42% University Education), compared with the general population. At 
that the time of these interviews only one person attending the lipid clinics we 
recruited our sample from had opted out of DNA testing; this bias in our sample may 
therefore, be due to the fact that those who attend lipid clinics are more likely to be of 
higher socio-economic status and more likely to be more highly educated (Jenkins et 
al., 2011, Weiner, 2006).    
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CONCLUSION 
In conclusion, this paper suggests that as far as index patients are concerned the 
usefulness of obtaining a molecular diagnosis for FH lies in its ability to confirm their 
personal and family history of CVD and to predict (younger) relatives’ future health 
risks. This observation raises a number of issues for future developments in genomics. 
If the perceived benefit of genetic testing for patients, who are successfully being 
treated for disease, lies in its ability to provide a seemingly conclusive aetiological 
explanation and predict other family members’ future risks, how will patients perceive 
DNA tests which provide a less conclusive aetiological account and may have less 
personal predictive power or few, if any, implications for their relatives? In other 
words, how will patients perceive the value of DNA tests which may provide them 
with ambiguous results (for example, variants of uncertain significance) or testing for 
single nucleotide polymorphisms, which have little, if any, predictive power for 
biological kin?  The increased use of direct to consumer DNA testing and the 
introduction of faster and cheaper whole genome and whole exome sequencing 
suggests that we may have to consider these issues in the near future.  
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